Daiichi Sankyo Company, Limited (4568.T)

5,464.00 +127.00 (+2.38%) At close: 03:15PM JST

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sunao Manabe D.V.M., Ph.D.	Group CEO & Executive Chairperson	280M	N/A	1954
Mr. Hiroyuki Okuzawa	President, COO & Representative Director	110M	N/A	1962
Dr. Shoji Hirashima	Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director	119M	N/A	1961
Mr. Koji Ogawa	Managing Executive Officer, Head of Global Corporate Planning & Management and CFO	N/A	N/A	N/A
Chiyu	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Hiroto Kashiwase	Managing Executive Officer & Head of Technology Division	N/A	N/A	N/A
Naoto Tsukaguchi	Gen. Counsel, Corp. Officer, Head of Global Legal & IP and VP of Leg. Aff. Dept.	N/A	N/A	N/A
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	N/A	N/A	N/A
Kentaro Asakura	Vice President of Corporate Communications Department	N/A	N/A	N/A
Ms. Marielle Cohard-Radice M.D.	Global Head of Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Corporate governance

Daiichi Sankyo Company, Limited’s ISS governance QualityScore as of 1 June 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.